APA (7th ed.) Citation

Boer, S. M. d., Wortman, B. G., Bosse, T., Powell, M. E., Singh, N., Hollema, H., . . . Pyman, J. (2018). Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Annals of Oncology, 29(2), 424. https://doi.org/10.1093/annonc/mdx753

Chicago Style (17th ed.) Citation

Boer, S M de, et al. "Clinical Consequences of Upfront Pathology Review in the Randomised PORTEC-3 Trial for High-risk Endometrial Cancer." Annals of Oncology 29, no. 2 (2018): 424. https://doi.org/10.1093/annonc/mdx753.

MLA (9th ed.) Citation

Boer, S M de, et al. "Clinical Consequences of Upfront Pathology Review in the Randomised PORTEC-3 Trial for High-risk Endometrial Cancer." Annals of Oncology, vol. 29, no. 2, 2018, p. 424, https://doi.org/10.1093/annonc/mdx753.